Yanlong Jiang

This study identifies ASB3 as an E3 ligase that suppresses antiviral immunity by ubiquitinating and degrading MAVS, thereby inhibiting IFN-I responses and promoting viral replication.

This study shows ASB3 worsens inflammatory bowel disease by destabilizing TRAF6 and altering gut microbiota, suggesting ASB3 inhibition could be a therapeutic strategy.

This study shows LGG metabolites activate ILC3 cells via AhR to produce IL-22, which prevents PEDV infection in piglets by enhancing intestinal cell proliferation and STAT3 signaling.